Plasma Risperidone-related Measures in Children and Adolescents with Oppositional Defiant/Conduct Disorders
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Therapeutic drug monitoring helps clinicians in choosing the right drug and adjust its dose in specific patients. To this end, we aimed to assess time patterns of risperidone and its metabolite, 9-hydroxyrisperidone, in children and adolescents with oppositional defiant and/or conduct disorder. Methods: We measured plasma concentrations of risperidone and 9-hydroxyrisperidone, their sum (active moiety, AM) and ratio, as well as plasma concentrations corrected for daily dose (C/D), from 140 children/adolescents with the above-mentioned disorders. We used Student’s t test to compare females versus males, patients under versus over 16-year-old, patients with lower versus higher than the median body weight, and patients with lower versus higher than the median body mass index (BMI). Two mixed-effects logistic regression models were fitted for risperidone/9- hydroxyrisperidone ratio and AM, respectively, by considering risperidone daily dose and patients’ demographic characteristics. Results: Females had higher 9-hydroxyrisperidone and AM plasma concentrations than males (p = 0.004 and p = 0.034). Younger patients had lower risperidone plasma concentration and risperidone/9-hydroxyrisperidone ratio (p = 0.02 and p = 0.021), but higher C/D 9-hydroxyrisperidone and AM than older patients (p = 0.013 and p = 0.043). Lower-weight patients had lower plasma risperidone and risperidone/9-hydroxyrisperidone ratio (p = 0.014 and p = 0.019), but higher C/D 9-hydroxyrisperidone concentration than heavier patients (p = 0.03). All these results could be accounted for by daily dose. Patients with lower and higher BMI did not differ significantly. Regression analyses showed that only risperidone daily dose predicted risperidone/9-hydroxyrisperidone ratio, whereas risperidone daily dose, sex, and age predicted AM. Conclusion: Clinicians prescribing risperidone need to consider sex, age, and weight, but not BMI when adjusting daily doses.
Abstract
Objective: Therapeutic drug monitoring helps clinicians in choosing the right drug and adjust its dose in specific patients. To this end, we aimed to assess time patterns of risperidone and its metabolite, 9-hydroxyrisperidone, in children and adolescents with oppositional defiant and/or conduct disorder. Methods: We measured plasma concentrations of risperidone and 9-hydroxyrisperidone, their sum (active moiety, AM) and ratio, as well as plasma concentrations corrected for daily dose (C/D), from 140 children/adolescents with the above-mentioned disorders. We used Student’s t test to compare females versus males, patients under versus over 16-year-old, patients with lower versus higher than the median body weight, and patients with lower versus higher than the median body mass index (BMI). Two mixed-effects logistic regression models were fitted for risperidone/9- hydroxyrisperidone ratio and AM, respectively, by considering risperidone daily dose and patients’ demographic characteristics. Results: Females had higher 9-hydroxyrisperidone and AM plasma concentrations than males (p = 0.004 and p = 0.034). Younger patients had lower risperidone plasma concentration and risperidone/9-hydroxyrisperidone ratio (p = 0.02 and p = 0.021), but higher C/D 9-hydroxyrisperidone and AM than older patients (p = 0.013 and p = 0.043). Lower-weight patients had lower plasma risperidone and risperidone/9-hydroxyrisperidone ratio (p = 0.014 and p = 0.019), but higher C/D 9-hydroxyrisperidone concentration than heavier patients (p = 0.03). All these results could be accounted for by daily dose. Patients with lower and higher BMI did not differ significantly. Regression analyses showed that only risperidone daily dose predicted risperidone/9-hydroxyrisperidone ratio, whereas risperidone daily dose, sex, and age predicted AM. Conclusion: Clinicians prescribing risperidone need to consider sex, age, and weight, but not BMI when adjusting daily doses.
참고문헌 (37)
- Rowe R, "The relationship between DSM-IV oppositional defiant disorder and conduct disorder : findings from the Great Smoky Mountains study", J Child Psychol Psychiatry, 43, pp.365~373 (2002)
- Noordermeer SD, "A systematic review and meta-analysis of neuroimaging in oppositional defiant disorder(ODD)and conduct disorder(CD)taking attention-deficit hyperactivity disorder(ADHD)into account", Neuropsychol Rev, 26, pp.44~72 (2016)
- Sasayama D, "Neuroanatomical correlates of attention-deficit-hyperactivity disorder accounting for comorbid oppositional defiant disorder and conduct disorder", Psychiatry Clin Neurosci, 64, pp.394~402 (2010)
- Nock MK, "Prevalence, subtypes, and correlates of DSM-IV conduct disorder in the National Comorbidity Survey Replication", Psychol Med, 36, pp.699~710 (2006)
- Nock MK, "Lifetime prevalence, correlates, and persistence of oppositional defiant disorder : results from the National Comorbidity Survey Replication", J Child Psychol Psychiatry, 48, pp.703~713 (2007)
- Gadow KD, "Risperidone added to parent training and stimulant medication : effects on attention-deficit", hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression, 2014, pp.53, 948~959.e1
- Harrison JN, "Antipsychotic medication prescribing trends in children and adolescents", J Pediatr Health Care, 26, pp.139~145 (2012)
- Persico AM, "Unmet needs in paediatric psychopharmacology : Present scenario and future perspectives", Eur Neuropsychopharmacol, 25, pp.1513~1531 (2015)
- Pringsheim T, "The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine", Can J Psychiatry, 60, pp.42~51 (2015)
- Simeon J, "A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.267~275 (2002)
- Nesvåg R, "Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication", Acta Psychiatr Scand, 114, pp.21~26 (2006)
- Hiemke C, "Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology : update 2017", Pharmacopsychiatry, 51, pp.9~62 (2018)
- Xiang Q, "Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety", J Clin Pharmacol, 50, pp.659~666 (2010)
- Yasui-Furukori N, "Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes", Drug Metab Dispos, 29, pp.1263~1268 (2001)
- Heykants J, "The pharmacokinetics of risperidone in humans: a summary", J Clin Psychiatry, 55(Suppl), pp.13~17 (1994)
- Ngamsamut N, "9-Hydroxyrisperidone-induced hyperprolactinaemia in Thai children and adolescents with Autism Spectrum Disorder", Basic Clin Pharmacol Toxicol, 119, pp.267~272 (2016)
- Nuntamool N, "Pharmacogenomics and efficacy of risperidone long-term treatment in Thai autistic children and adolescents", Basic Clin Pharmacol Toxicol, 121, pp.316~324 (2017)
- Roke Y, "Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone", J Child Adolesc Psychopharmacol, 22, pp.432~439 (2012)
- Roke Y, "The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys", Pharmacogenet Genomics, 23, pp.487~493 (2013)
- Sukasem C, "Impact of pharmacogenetic markers of CYP2D6 and DRD2 on prolactin response in risperidone-treated Thai children and adolescents with autism spectrum disorders", J Clin Psychopharmacol, 36, pp.141~146 (2016)
- Vanwong N, "Impact of CYP2D6 polymorphism on steady-state plasma levels of risperidone and 9-hydroxyrisperidone in Thai children and adolescents with autism spectrum disorder", J Child Adolesc Psychopharmacol, 27, pp.185~191 (2017)
- Aichhorn W, "Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents", J Child Adolesc Psychopharmacol, 17, pp.665~674 (2007)
- Calarge CA, "Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents", J Child Adolesc Psychopharmacol, 21, pp.163~169 (2011)
- Balant-Gorgia AE, "Therapeutic drug monitoring of risperidone using a new, rapid HPLC method : reappraisal of interindividual variability factors", Ther Drug Monit, 21, pp.105~115 (1999)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Publishing
- Bader W, "Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (HPLC) and electrochemical detection", Pharmacopsychiatry, 38 (2005)
- Paul LD, "Richtlinie der GTFCh zur qualitätssicherung bei forensisch-toxikologischen untersuchungen", Toxichem Krimtech, 76, pp.142~176 (2009)
- "Bioanalytical method validation guidance for industry" (2001)[URL]
- ICH International Conference on harmonization, "ICH Harmonised tripartite guideline. Validation of analytical procedures:test and methodology Q2(R1)", Abstracts of the 3rd International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, pp.519~ (1996)
- Genovese CR, "False discovery control with p-value weighting", Biometrika, 93, pp.509~524 (2006)
- Schoretsanitis G, "A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone", Expert Rev Clin Pharmacol, 10, pp.965~981 (2017)
- Paulzen M, "Body mass index(BMI)but not body weight is associated with changes in the metabolism of risperidone;A pharmacokinetics-based hypothesis", Psychoneuroendocrinology, 73, pp.9~15 (2016)
- 강남인, "Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial", Clinical Psychopharmacology and Neuroscience, 14(3), pp.261~269 (2016), 대한정신약물학회
- Lostia AM, "Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone : correlation between drug concentration and clinical response", Ther Drug Monit, 31, pp.475~481 (2009)
- Ulku Akyol Ardic, "Efficacy and Safety Profile of Risperidone Long-acting Injection in Adolescents in a Real-life Setting", Clinical Psychopharmacology and Neuroscience, 16(1), pp.57~61 (2018), 대한정신약물학회[DOI]
- Sevcan Karakoç Demirkaya, "A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder", Clinical Psychopharmacology and Neuroscience, 15(4), pp.328~336 (2017), 대한정신약물학회[DOI]
- Myrthala Juárez-Treviño, "Clozapine in the Treatment of Aggression in Conduct Disorder in Children and Adolescents: A Randomized, Double-blind, Controlled Trial", Clinical Psychopharmacology and Neuroscience, 17(1), pp.43~53 (2019), 대한정신약물학회[DOI]